tiprankstipranks
Trending News
More News >

Protagonist Therapeutics Stockholders Approve Key Proposals

Story Highlights
Protagonist Therapeutics Stockholders Approve Key Proposals

Don’t Miss TipRanks’ Half-Year Sale

Protagonist Therapeutics ( (PTGX) ) has provided an update.

At the Annual Meeting, Protagonist Therapeutics‘ stockholders voted on three key proposals. The first proposal involved electing two Class III directors, Harold E. Selick, Ph.D., and Bryan Giraudo, to serve until the 2028 Annual Meeting, both of whom were elected. The second proposal, regarding the approval of executive compensation, was passed. The third proposal, ratifying Ernst & Young LLP as the company’s independent auditor for the fiscal year ending December 31, 2025, was also approved.

The most recent analyst rating on (PTGX) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Protagonist Therapeutics stock, see the PTGX Stock Forecast page.

Spark’s Take on PTGX Stock

According to Spark, TipRanks’ AI Analyst, PTGX is a Neutral.

Protagonist Therapeutics’ overall score is driven by a mix of financial performance and technical analysis. The positive trend in stock price is offset by financial instability, high valuation metrics, and the absence of consistent revenue growth.

To see Spark’s full report on PTGX stock, click here.

More about Protagonist Therapeutics

Average Trading Volume: 1,022,413

Technical Sentiment Signal: Buy

Current Market Cap: $3.37B

For a thorough assessment of PTGX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1